-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HFB-200603 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.HFB-200603 in Colorectal CancerDrug Details:HFB-200603 is under development for the treatment of solid tumor, renal cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ficlatuzumab in Oropharyngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ficlatuzumab in Oropharyngeal Cancer Drug Details: Ficlatuzumab (AV-299, SCH 900105) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – KT-333 in Cutaneous T-Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.KT-333 in Cutaneous T-Cell Lymphoma Drug Details:KT-333 is under development for the treatment of peripheral T...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lipocurc in Prostate Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Lipocurc in Prostate Cancer Drug Details:Liposomal curcumin is under development for the treatment of metastatic cancer,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STT-003 in Melanoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STT-003 in Melanoma Drug Details: STT-003 is under development for the treatment of head...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – STT-003 in Colon Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STT-003 in Colon Cancer Drug Details: STT-003 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AV-203 in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AV-203 in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: AV-203 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ficlatuzumab in Recurrent Head And Neck Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ficlatuzumab in Recurrent Head And Neck Squamous Cell Carcinoma Drug Details: Ficlatuzumab (AV-299, SCH 900105)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ficlatuzumab in Nasopharyngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ficlatuzumab in Nasopharyngeal Cancer Drug Details: Ficlatuzumab (AV-299, SCH 900105) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AV-203 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AV-203 in Ovarian Cancer Drug Details: AV-203 is under development for the treatment of metastatic...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.